SEC 13F Intelligence

Managers / Q3 2023 · view latest →

HighVista Strategies LLC

CIK 0001335325 · 200 CLARENDON STREET, 50TH FLOOR, BOSTON, MA, 02116 · 617-406-6500

Reported Value
$216M
Q3 2023
Positions
132
Filings on Record
30
2019–present window
Filed
Nov 14, 2023
original filing

Summary

Highvista Strategies LLC reported $216M in U.S.-listed holdings across 132 positions for Q3 2023.

Its largest position, DBC, represents 16.6% of the portfolio.

Compared with Q2 2023, the fund opened 38 new positions and exited 40.

Portfolio Metrics

Turnover
+29.4%
vs prior filed quarter
Top-10 Concentration
+35.1%
share of reported value
Largest Position
+16.6%
Invesco Db Commdy Indx Trck
New / Exited
38 / 40
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $116MQ4 ’18Q1 ’19: $123MQ2 ’19: $195MQ3 ’19: $147MQ4 ’19: $132MQ4 ’19Q1 ’20: $108MQ2 ’20: $121MQ3 ’20: $137MQ4 ’20: $157MQ4 ’20Q1 ’21: $135MQ2 ’21: $141MQ3 ’21: $151MQ4 ’21: $126MQ4 ’21Q1 ’22: $157MQ2 ’22: $166MQ3 ’22: $175MQ4 ’22: $168MQ4 ’22Q1 ’23: $123MQ2 ’23: $219MQ3 ’23: $216MQ4 ’23: $276MQ4 ’23Q1 ’24: $280MQ2 ’24: $274MQ3 ’24: $290MQ4 ’24: $269MQ4 ’24Q1 ’25: $260MQ2 ’25: $272MQ3 ’25: $408MQ4 ’25: $388MQ4 ’25Q1 ’26: $362Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 63.2%ETP: 16.6%ADR: 10.0%Other: 9.9%REIT: 0.3%
  • Common Stock · 63.2% · $137M
  • ETP · 16.6% · $36M
  • ADR · 10.0% · $22M
  • Other · 9.9% · $21M
  • REIT · 0.3% · $548,564

Quarter-over-Quarter Changes full breakdown →

vs Q2 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CAPRI HOLDINGS LIMITEDNEW+77.7K77.7K+$4M$4M
SPLKCHFSPLUNK INCNEW+27.6K27.6K+$4M$4M
GPCRSTRUCTURE THERAPEUTICS INCNEW+74.8K74.8K+$4M$4M
AMEDAMEDISYS INCNEW+39.3K39.3K+$4M$4M
IDYAIDEAYA BIOSCIENCES INCNEW+126.8K126.8K+$3M$3M
IMGNEURIMMUNOGEN INCNEW+144.8K144.8K+$2M$2M
ISIIONIS PHARMACEUTICALS INCNEW+48.5K48.5K+$2M$2M
IM8NINSMED INCNEW+80.0K80.0K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2023

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1DBCINVESCO DB COMMDY INDX TRCKhistory →UNIT16.59%$36M1.44M
2ATVIEURACTIVISION BLIZZARD INChistory →COM2.67%$6M61.5K
3VMWEURVMWARE INChistory →CL A COM2.59%$6M33.6K
4ACIALBERTSONS COS INChistory →COMMON STOCK1.99%$4M188.8K
5IMVTIMMUNOVANT INChistory →COM1.90%$4M106.9K
6CAPRI HOLDINGS LIMITEDSHS1.89%$4M77.7K
7HORIZON THERAPEUTICS PUB LSHS1.87%$4M35.0K
8SPLKCHFSPLUNK INChistory →COM1.87%$4M27.6K
9SGENUSDSEAGEN INChistory →COM1.87%$4M19.0K
10AXSMAXSOME THERAPEUTICS INChistory →COM1.84%$4M57.0K
11GPCRSTRUCTURE THERAPEUTICS INChistory →SPONSORED ADS1.75%$4M74.8K
12AMEDAMEDISYS INChistory →COM1.70%$4M39.3K
13IDYAIDEAYA BIOSCIENCES INChistory →COM1.58%$3M126.8K
14MLTXMOONLAKE IMMUNOTHERAPEUTICShistory →CLASS A ORD1.58%$3M59.8K
15MSFTMICROSOFT CORPhistory →COM1.46%$3M10.0K
16TXNMPNM RES INChistory →COM1.44%$3M69.9K
17OLMAOLEMA PHARMACEUTICALS INChistory →COM1.42%$3M247.9K
18LEGNLEGEND BIOTECH CORPhistory →SPONSORED ADS1.38%$3M44.3K
19MERUS N VCOM1.34%$3M122.6K
20INDIVIOR PLCORD1.31%$3M130.0K
21ACLXGBXARCELLX INChistory →COMMON STOCK1.30%$3M78.0K
22CYMABAY THERAPEUTICS INCCOM1.24%$3M180.3K
23NUVLNUVALENT INChistory →COM1.15%$2M54.1K
24IMGNEURIMMUNOGEN INChistory →COM1.06%$2M144.8K
25AMBRX BIOPHARMA INCSPONSORED ADS1.03%$2M193.7K
26ISIIONIS PHARMACEUTICALS INChistory →COM1.02%$2M48.5K
27GOOGALPHABET INChistory →CAP STK CL C1.02%$2M16.6K
28CRMSALESFORCE INCCOM0.98%$2M10.5K
29IMCRIMMUNOCORE HLDGS PLCADS0.96%$2M39.8K
30IM8NINSMED INCCOM PAR $.010.93%$2M80.0K
31VVISA INCCOM CL A0.93%$2M8.7K
32RPTXREPARE THERAPEUTICS INCCOM0.92%$2M165.2K
33DVAXDYNAVAX TECHNOLOGIES CORPCOM NEW0.91%$2M133.0K
34IMRXIMMUNEERING CORPCLASS A COM0.90%$2M254.5K
35XPOXPO INCCOM0.90%$2M26.2K
36COGTCOGENT BIOSCIENCES INCCOM0.90%$2M198.6K
37MUMICRON TECHNOLOGY INCCOM0.89%$2M28.2K
38BCYCBICYCLE THERAPEUTICS PLCSPONSORED ADS0.86%$2M92.4K
39ELVNENLIVEN THERAPEUTICS INCCOM0.79%$2M124.6K
40X0M1XOMA CORP DELCOM NEW0.78%$2M118.9K
41VRDNVIRIDIAN THERAPEUTICS INCCOM0.74%$2M104.8K
42KARUNA THERAPEUTICS INCCOM0.71%$2M9.1K
43MAMASTERCARD INCORPORATEDCL A0.69%$1M3.7K
44USX1UNITED STATES STL CORP NEWCOM0.64%$1M42.9K
45FCNCAFIRST CTZNS BANCSHARES INC NCL A0.61%$1M961
46TRANSOCEAN LTDREG SHS0.60%$1M158.4K
47TEVATEVA PHARMACEUTICAL INDS LTDSPONSORED ADS0.59%$1M124.3K
48METAMETA PLATFORMS INCCL A0.58%$1M4.2K
49FISVFISERV INCCOM0.57%$1M11.0K
50XENEXENON PHARMACEUTICALS INCCOM0.56%$1M35.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$362M156May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$388M145Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$408M148Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$272M146Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$260M148May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$269M137Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$290M142Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$274M138Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$280M131May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$276M126Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$216M132Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$219M134Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$123M108May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$168M105Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$175M113Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$166M110Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$157M86May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$126M69Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$151M127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$141M116Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$135M125May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$157M117Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$137M113Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$121M100Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$108M65May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$132M119Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$147M126Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$195M108Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$123M112May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$116M113Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.